Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Intellia Therapeutics (NTLA – Research ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...

Intellia Therapeutics (NASDAQ:NTLA) said it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z ...